Trial | NCT00242359  Report issue

Official Title

A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Withdrawn

  • Intervention/Treatment

    omalizumab ...

  • Study Participants

    0
Management of animal induced occupational asthma is mainly avoidance, but this is not feasible for many occupations. Treatment with avoidance and conventional treatment is also not always successful. Omalizumab is FDA approved for the treatment of allergic asthma and may be effective at reducing symptoms and disease progression in the animal handlers population.
Study Started
Nov 30
2005
Primary Completion
Jan 31
2009
Study Completion
Jan 31
2009
Last Update
Jul 10
2019

Drug omalizumab

omalizumab Other

open-label

Criteria 

Inclusion Criteria:

ages 18-65
occupation that involves close contact with animals
stable dose of ICS for 30 days
Skin test positive to one or more animals
evidence of asthma on spirometry
demonstrate PEFR variability-

Exclusion Criteria:

on allergen immunotherapy
on prohibited medications
unstable asthma
recent URI
known hypersensitivity to omalizumab-
No Results Posted